Comprehensive Geriatric Assessment in Chronic Disease Management for Older Adults in China: A Registry Study （CGACDM - Older Adults in China）
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,000
- 主要终点
- Major adverse events (MAE)
研究概览
简要总结
With the continuous development of China's economy and the improvement of medical standards, the life expectancy of the Chinese population has significantly increased. Against the backdrop of accelerating aging in China, the incidence of age-related chronic non-communicable diseases (NCDs), such as cardiovascular and cerebrovascular diseases and chronic respiratory diseases, has risen remarkably. These diseases are characterized by multiple comorbidities, high disability rates, and high mortality rates, severely compromising the quality of life of older adults, exacerbating family burdens, and straining healthcare systems. This constitutes one of the major challenges faced by aging societies. Therefore, early detection and intervention of chronic diseases in older adults are critical measures to address population aging.
Comprehensive geriatric assessment (CGA), a core specialty of geriatric medicine, serves as a fundamental framework for the clinical identification of geriatric syndromes and multidisciplinary management. It is emerging as a key pathway to promote "healthy aging." Guided by this premise, this study aims to explore the application value of CGA in managing chronic diseases among older adults, with the goal of achieving full-cycle management for early detection, diagnosis, and treatment of chronic conditions in China's elderly population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 60 years or older
- •Diagnosed with chronic diseases in the circulatory, respiratory, digestive, nervous, or endocrine systems, consistent with corresponding disease diagnostic criteria;
- •Availability of complete medical records;
- •Clear consciousness and ability to independently answer questions;
- •Signed informed consent form.
排除标准
- •Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
- •Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.
- •Current participation in a randomised interventional clinical trial.
结局指标
主要结局
Major adverse events (MAE)
时间窗: These data is collected during follow-up visit at 3/6/12/24/36 months after discharge
Major adverse events (MAE) in overall population, defined as composite of all-cause death, Heart Failure hospitalization, recurrent myocardial infarction, stroke, etc.
次要结局
未报告次要终点